Novel therapeutic modalities show promise in oncology. Brightpath Biotherapeutics’ BCMA CAR-natural killer T cell candidate BP-2202 received FDA orphan drug designation for multiple myeloma, marking advancement in cell therapies. Additionally, a fusion 'superkine' combining IL-24S and IL-15 induces apoptosis in glioblastoma cells and enhances antitumor immunity, suggesting potential breakthroughs for this aggressive brain cancer subtype. These developments highlight expanding immunotherapeutic strategies beyond conventional approaches.